MX2010002410A - Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te. - Google Patents

Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.

Info

Publication number
MX2010002410A
MX2010002410A MX2010002410A MX2010002410A MX2010002410A MX 2010002410 A MX2010002410 A MX 2010002410A MX 2010002410 A MX2010002410 A MX 2010002410A MX 2010002410 A MX2010002410 A MX 2010002410A MX 2010002410 A MX2010002410 A MX 2010002410A
Authority
MX
Mexico
Prior art keywords
products
methods
oral compositions
composition
human
Prior art date
Application number
MX2010002410A
Other languages
English (en)
Inventor
Paul John Rennie
Jeffrey Warren Clymer
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2010002410A publication Critical patent/MX2010002410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención comprende una composición oral. Más particularmente, se refiere a un método para proporcionar a un ser humano los beneficios de energía, alivio del estrés y mejora del estado de ánimo; el método comprende los pasos de administrar a un ser humano una composición que comprende de aproximadamente 450 IU a aproximadamente 500,000 IU de colecalciferol, por dosis de la composición y un extracto de té.
MX2010002410A 2007-09-04 2008-09-04 Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te. MX2010002410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96741207P 2007-09-04 2007-09-04
PCT/US2008/075199 WO2009032888A2 (en) 2007-09-04 2008-09-04 Oral compositions, products, and methods of use

Publications (1)

Publication Number Publication Date
MX2010002410A true MX2010002410A (es) 2010-03-26

Family

ID=40090141

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010002498A MX2010002498A (es) 2007-09-04 2008-09-04 Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
MX2010002410A MX2010002410A (es) 2007-09-04 2008-09-04 Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010002498A MX2010002498A (es) 2007-09-04 2008-09-04 Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.

Country Status (9)

Country Link
US (2) US20090060878A1 (es)
EP (2) EP2194989A1 (es)
CN (2) CN101801389A (es)
AU (2) AU2008296311B2 (es)
BR (2) BRPI0816465A2 (es)
CA (2) CA2698517A1 (es)
MX (2) MX2010002498A (es)
RU (2) RU2479316C2 (es)
WO (2) WO2009032888A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178106B2 (en) * 2009-03-30 2012-05-15 Mary Kay Inc. Topical skin care formulations
HUE025567T2 (en) * 2011-08-19 2016-02-29 Maria Clementine Martin Klosterfrau Vertriebsges Mbh Agents containing vasoconstrictors for combination therapy
WO2013052101A1 (en) * 2011-10-03 2013-04-11 Kelly Foods Corporation Probiotic composition for pets and method of providing the same
US20130101634A1 (en) * 2011-10-12 2013-04-25 Deerland Enzymes, Inc. Compositions and methods for reducing microbial overgrowth in the small intestines
WO2013118391A1 (ja) * 2012-02-10 2013-08-15 キリン協和フーズ株式会社 アムラ由来成分含有果実系飲食品
US20130273182A1 (en) * 2012-04-12 2013-10-17 Po-Lun Wang A Herbal Extract for Treating Fatty Liver Disease and a Medication Thereof
US9616124B2 (en) * 2014-07-17 2017-04-11 Jonathan S. Nimitz Antiviral supplement compositions and methods of use
WO2016037166A1 (en) * 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
WO2016195526A1 (ru) * 2015-06-03 2016-12-08 Людмила Борисовна ТИМИРОВА Успокаивающая композиция, понижающая возбудимость при половой охоте у кошек и собак
DE102016105369A1 (de) * 2016-03-22 2017-09-28 Bernd Büter Erzeugnis, insbesondere Nahrungsmittelzusatz, Futtermittel oder Tierfutterzusatz und Verfahren zu dessen Herstellung
US20210368843A1 (en) * 2016-08-04 2021-12-02 Seattle Gummy Company Mineral compositions and methods of making and using thereof
WO2018169497A1 (en) * 2017-03-17 2018-09-20 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Spray formulation comprising cholecalciferol (vitamin d3) with improved stability
CA3066620A1 (en) 2017-06-08 2018-12-13 Allergyintellect, Inc Vitamin d compounds and methods of using the same
CN108813608A (zh) * 2018-05-25 2018-11-16 陕西黄龙国寿堂生物工程有限公司 一种沙棘刺五加膏的制作方法
CN109549993A (zh) * 2018-12-29 2019-04-02 西安高科陕西金方药业公司 直肠或雾化吸入给药射干抗病毒制剂和制备及用途
CN110051758A (zh) * 2019-05-20 2019-07-26 西安高科陕西金方药业公司 一种射干抗病毒口服制剂及其制备方法
DE102019218199A1 (de) * 2019-11-25 2021-05-27 Sternenzym Gmbh & Co. Kg Verfahren zum Behandeln von Kaffeebohnen, sowie Kaffeebohne, die gemäß diesem Verfahren hergestellt wurde
EP4117697A1 (en) * 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
US20240131036A1 (en) * 2020-07-02 2024-04-25 The Uab Research Foundation Compositions and methods of treating conditions
IT202000018949A1 (it) * 2020-08-03 2022-02-03 Arterra Bioscience S P A Estratto derivato da bucce di punica granatum per la prevenzione e il trattamento di infezioni virali
IT202100010409A1 (it) * 2021-04-23 2022-10-23 Esserre Pharma Srl Composizione comprendente un fitocomplesso da melograno e suoi usi
CN115154502B (zh) * 2022-08-02 2023-11-03 黑龙江乌苏里江制药有限公司 一种抗炎组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
RU2033160C1 (ru) * 1991-04-08 1995-04-20 Апуховская Лариса Ивановна Способ производства витамина d3 -белкового препарата "видеин"
GB9203535D0 (en) * 1992-02-19 1992-04-08 Leo Pharm Prod Ltd Novel treatment iii
US6187764B1 (en) * 1997-05-05 2001-02-13 Angelina Pinal Buttz A and D vitamins and their metabolites: A new treatment for seasonal allergic rhinitis and atopy
GB0016173D0 (en) * 2000-06-30 2000-08-23 Nestle Sa Confectionery product containing active ingredients
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
CA2470603A1 (en) * 2001-12-19 2003-07-03 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US6572903B1 (en) * 2002-05-08 2003-06-03 4 Seasons Wildlife Nutrition, Llc Wildlife nutritional supplement
WO2004067526A1 (ja) * 2003-01-31 2004-08-12 Teijin Pharma Limited （２３Ｓ）－１αーヒドロキシー２７－ノルー２５－メチレンビタミンＤ３－２６，２３－ラクトンの結晶およびその製造方法
RU2241437C1 (ru) * 2003-04-28 2004-12-10 Открытое акционерное общество "Косметическое объединение "Свобода" Зубная паста "пародонтол" с экстрактом зеленого чая, фтором, витаминами а и е
KR20040101695A (ko) * 2003-05-26 2004-12-03 (주)헬스마스터 산모용 특수영양식품
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
JP2005239694A (ja) * 2004-02-27 2005-09-08 Taiyo Kagaku Co Ltd 抗ストレス組成物
US20050260285A1 (en) * 2004-05-21 2005-11-24 Dimateeo-Leggio Giovina Healthy prostate formula
WO2006048457A1 (en) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Probiotica and polyphenol
RU2290943C2 (ru) * 2004-12-20 2007-01-10 Дмитрий Николаевич Мясников Композиция, обладающая тонизирующим действием
US7442394B2 (en) * 2005-05-02 2008-10-28 University Of South Florida Combined effects of nutrients on proliferation of stem cells
WO2006130971A1 (en) * 2005-06-07 2006-12-14 Vivabody Formulations Ltd. Diet supplement for weight loss, energy and improved mental focus
US20070122477A1 (en) * 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
ATE476104T1 (de) * 2005-11-25 2010-08-15 Dsm Ip Assets Bv Verwendung von 25-hydroxy-vitamin d3 zur verbesserung der vitalität von tieren
EP1891944A1 (en) * 2006-07-24 2008-02-27 Association pour la recherche à l'IGBMC (ARI) Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases
JP5501956B2 (ja) * 2007-04-25 2014-05-28 シトクロマ インコーポレイテッド ビタミンｄ化合物およびワックス状担体を含有する制御放出性経口組成物
US8318708B2 (en) * 2007-11-06 2012-11-27 Salk Institute For Biological Studies Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis

Also Published As

Publication number Publication date
CA2698514A1 (en) 2009-03-12
BRPI0816465A2 (pt) 2015-03-24
MX2010002498A (es) 2010-03-26
BRPI0816350A2 (pt) 2015-02-24
CA2698517A1 (en) 2009-03-12
RU2010105123A (ru) 2011-10-20
CN101801389A (zh) 2010-08-11
US20090060879A1 (en) 2009-03-05
RU2010105122A (ru) 2011-10-10
WO2009032888A3 (en) 2009-12-03
EP2194990A2 (en) 2010-06-16
AU2008296310A1 (en) 2009-03-12
WO2009032888A2 (en) 2009-03-12
RU2479313C2 (ru) 2013-04-20
EP2194989A1 (en) 2010-06-16
CN101795693A (zh) 2010-08-04
RU2479316C2 (ru) 2013-04-20
AU2008296311A1 (en) 2009-03-12
AU2008296311B2 (en) 2014-07-03
US20090060878A1 (en) 2009-03-05
WO2009032887A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
MX2010002410A (es) Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.
CR20120625A (es) Métodos de tratamiento contra el cáncer pancreático
MY151018A (en) Use of nutritional compositions for preventing disorders
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MY155299A (en) Oral dosage composition
MY153408A (en) Novel methods
MX2009006695A (es) P-mentan-3-carboxamida sustituida con nitrogeno y sus usos.
IN2014MN00139A (es)
MX367131B (es) Sales de xantilio 3,6-disustituidas.
CA2632207C (en) Use of calcitonin for the treatment of ra
MX2010009848A (es) Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
IL168308A (en) Compositions containing roflumilast and formoterol
TW200719903A (en) Compositions for the treatment of neoplasms
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
GB2446341A (en) Method and system for transdermal drug delivery
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
MX2012006217A (es) Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne.
TW200512000A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
WO2007135123A3 (en) Mirtazapine for the treatment of neuropathic pain
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
WO2009015447A3 (en) Polyacetal-carboxylic acids in the treatment of cancer and auto-immune disorders

Legal Events

Date Code Title Description
HH Correction or change in general